🔎 Trials Near Me

Home › Pancreatic Cancer › NCT07513116

Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening

Recruiting

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria

* Participants ≥ 18 years old. Participants under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits.
* Participants evaluated and classified as high risk for pancreatic cancer through a High-Risk Pancreatic Cancer Clinic or High-Risk Pancreatic Cyst Clinic, based on established clinical assessment and risk stratification.
* High-risk status may include one or more of the following:

  * Hereditary cancer syndromes or known pathogenic germline mutations associated with pancreatic cancer risk
  * Family history of pancreatic ductal adenocarcinoma (PDAC)
  * Presence of pancreatic cysts or precursor lesions (e.g., IPMN, MCN)
  * New-onset diabetes mellitus is considered suspicious for pancreatic cancer
  * History of recurrent or chronic pancreatitis
* Eligibility and surveillance risk assessment must be consistent with NCCN (National Comprehensive Cancer Network) Guidelines for Pancreatic Cancer Screening in High- Risk Individuals.
* Participants are able to understand and are willing to sign a written informed consent document.
* Both English-speaking and non-English-speaking participants are eligible for participation
* Participants are willing to make a change in eating time patterns.
* Participants are willing to provide App-tracked fasting time data over the course of the study.

Exclusion Criteria

* BMI \< 18.5 Kg/m2
* Documented history of symptomatic hypoglycemia
* Pregnant or breastfeeding women
* Cognitively impaired individuals

About the study

To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.

What is being tested

Sponsor: M.D. Anderson Cancer Center · Participants: 20 · Started: Jun 10, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07513116

Locations in the U.S.

TexasMD Anderson Cancer Center, Houston

Conditions

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.